Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-06: Tiragolumab + Atezolizumab + Chemotherapy vs Pembrolizumab + Chemotherapy in 1L Non-Squamous NSCLC
NCT04619797Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 21
01
Overview
A Phase 3 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Dec 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04619797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619797.